ライフサイエンスコーパス: respiratory failure

1 roup (upper gastrointestinal haemorrhage and respiratory failure).

2 domized Evaluation of Sedation Titration for Respiratory Failure).

3 nt disease characterized by sepsis and acute respiratory failure.

4 ely selected COVID-19 patients with advanced respiratory failure.

5 he validation cohort regarding their risk of respiratory failure.

6 end up in interstitial pneumonia and severe respiratory failure.

7 imary cause of death from opioid overdose is respiratory failure.

8 istent viral presence, hyperinflammation and respiratory failure.

9 ressive muscle weakness, cardiomyopathy, and respiratory failure.

10 to stabilize severe cardiocirculatory and/or respiratory failure.

11 nfantile cardiomyopathy, lactic acidosis and respiratory failure.

12 cterized by progressive muscular atrophy and respiratory failure.

13 s per year for tracheostomy-related to acute respiratory failure.

14 Fifteen patients had gait loss, and 6 had respiratory failure.

15 sociated with muscle weakness, paralysis and respiratory failure.

16 tio, 1.94; 95% CI, 1.18-3.18; p = 0.009) and respiratory failure.

17 ndrome on day 1 and day 2 of acute hypoxemic respiratory failure.

18 ted in patients with severe refractory acute respiratory failure.

19 -existing cardiac or respiratory arrest, and respiratory failure.

20 care is necessary during exacerbations with respiratory failure.

21 e placed on VV ECMO for refractory hypoxemic respiratory failure.

22 equency, often followed by gasping and fatal respiratory failure.

23 tor neuron death, paralysis and, ultimately, respiratory failure.

24 rstitial and airspace inflammation, or acute respiratory failure.

25 naloxone upon detection of overdose-induced respiratory failure.

26 ffuse lung diseases presenting with neonatal respiratory failure.

27 disease, resulting in pulmonary fibrosis and respiratory failure.

28 nts with COPD and chronic stable hypercapnic respiratory failure.

29 l benefits in unselected patients with acute respiratory failure.

30 poreal membrane oxygenation for severe acute respiratory failure.

31 la is increasingly used in the management of respiratory failure.

32 used to sustain life in patients with acute respiratory failure.

33 unocompromised patients with hypoxemic acute respiratory failure.

34 ight and weight and mild chronic restrictive respiratory failure.

35 eatment with antitoxin, some patients suffer respiratory failure.

36 y or noninvasive ventilation) in adults with respiratory failure.

37 available for children at risk of death from respiratory failure.

38 xtracorporeal membrane oxygenation for acute respiratory failure.

39 fort in adult patients recovering from acute respiratory failure.

40 rized by repeated lung infections leading to respiratory failure.

41 volution toward pleuropulmonary fibrosis and respiratory failure.

42 vary, ranging from asymptomatic infection to respiratory failure.

43 nous extracorporeal membrane oxygenation for respiratory failure.

44 are used in adults with or at risk of acute respiratory failure.

45 ive sleep apnea syndrome, or other causes of respiratory failure.

46 nit, or 3) received a tracheostomy for acute respiratory failure.

47 ane oxygenation initiation for children with respiratory failure.

48 tion and its association with development of respiratory failure.

49 re brain dysfunctions that could precipitate respiratory failure.

50 only previously healthy children with acute respiratory failure.

51 ventilation via endotracheal tube for acute respiratory failure.

52 agnosis, and <1% (95% CI, 0%-1%) resulted in respiratory failure.

53 lammatory response that can lead to terminal respiratory failure.

54 verse group of intubated patients with acute respiratory failure.

55 ssue inflammation with the aim of preventing respiratory failure.

56 de tobacco use, coronary artery disease, and respiratory failure.

57 more useful predictor of mortality in acute respiratory failure.

58 B use could predict the development of acute respiratory failure.

59 upport for COVID-19-related acute hypoxaemic respiratory failure.

60 symptoms ranging from mild through fulminant respiratory failure.

61 for gallbladder empyema and died from severe respiratory failure.

62 to increased likelihood for lung injury and respiratory failure.

63 with coronavirus disease 2019 related acute respiratory failure.

64 erapy alone in patients with acute hypoxemic respiratory failure.

65 izing cellulitis, systemic inflammation, and respiratory failure.

66 ystic remodeling of the lung and progressive respiratory failure.

67 ays, whereas 2 deteriorated with progressive respiratory failure.

68 rging data, and review seminal literature on respiratory failure.

69 et for the prevention and treatment of acute respiratory failure.

70 ts exposed to supplemental oxygen to prevent respiratory failure.

71 s for supportive management of acute hypoxic respiratory failure.

72 mia (14 [6%]; one related to treatment), and respiratory failure (14 [6%]).

73 8%, $21,995), renal failure (2.8%, $19,201), respiratory failure (2.7%, $25,169), and hemorrhage (3.3

74 nous extracorporeal membrane oxygenation for respiratory failure, 2) veno-arterial extracorporeal mem

75 3 [74.0% reduction]; P < .001 for trend) and respiratory failure (29.9 PACs placed per 1000 admission

76 ), patient's wishes (56.0%), and etiology of respiratory failure (37.7%) were factors that influenced

77 3% vs 8.6%; P = .004) or prolonged hypoxemic respiratory failure (39.4% vs 11.4%; P = .001) compared

78 okalemia (22 caspofungin vs 13 fluconazole), respiratory failure (6 caspofungin vs 9 fluconazole), an

79 All the patients were admitted for hypoxemic respiratory failure; 75% (18 patients) needed mechanical

80 ociated with a greater risk of postoperative respiratory failure (8.2% versus 6.2%, P<0.0001) and acu

81 .Conclusions: In patients receiving ECMO for respiratory failure, a large relative decrease in Pa(CO(

82 ren (<18 years) with influenza infection and respiratory failure across 34 pediatric intensive care u

83 missions (n = 524; 50%) were marked by acute respiratory failure, acute kidney injury, or sepsis.

84 oses of pneumonia, or principal diagnoses of respiratory failure, acute respiratory distress syndrome

85 in the first 5 postoperative days, including respiratory failure, acute respiratory distress syndrome

86 ammation (n = 104, 35.6%) related to sepsis, respiratory failure, acute respiratory distress syndrome

87 relative risk, 2.63; 95% CI, 1.30-5.30), and respiratory failure (adjusted relative risk, 1.19; 95% C

88 secutive patients with acute hypoxic de novo respiratory failure admitted to a single center and cand

89 HR], 2.18; 95% CI, 1.41-3.39) and death from respiratory failure (aHR, 2.50; 95% CI, 1.56-4.01) compa

90 f nonintubated patients with acute hypoxemic respiratory failure (AHRF).

91 ing mechanical ventilation for acute hypoxic respiratory failure, airway pressure release ventilation

92 COVID-19 patients with hyperinflammation and respiratory failure, also on mechanical ventilation.

93 velop acute lung injury that can progress to respiratory failure, although multiorgan failure can als

94 ial of extracorporeal life support for acute respiratory failure and (2) the use of extracorporeal li

95 Adults with acute respiratory failure and at least 24 hours of invasive me

96 COVID-19]), but the mechanisms of subsequent respiratory failure and complicating renal and myocardia

97 ibility locus in patients with Covid-19 with respiratory failure and confirmed a potential involvemen

98 t some individuals develop severe pneumonia, respiratory failure and death(1-4).

99 responses are thought to be major causes of respiratory failure and death, how they relate to lung i

100 ngitudinally followed for the development of respiratory failure and death, we reveal that IFN-lambda

101 ance, disrupted gas exchange, and ultimately respiratory failure and death.

102 ung injury and thereby reduce progression to respiratory failure and death.

103 nous extracorporeal membrane oxygenation for respiratory failure and extracorporeal cardiopulmonary r

104 Pneumonia is a lung disease that can cause respiratory failure and hypoxia and is a common complica

105 f lung graft-related serious adverse events (respiratory failure and major pulmonary-related infectio

106 h occurred in a 59-year-old woman with acute respiratory failure and mean pulmonary artery pressure o

107 an aortic dissection, complicated by hypoxic respiratory failure and oliguric renal failure.

108 n profound muscle weakness (which can invoke respiratory failure and other critical complications) ca

109 dae associates with critical illness such as respiratory failure and periodontitis, illustrating the

110 eosinophil count correlates with severity of respiratory failure and predicts risk of subsequent exac

111 MPV) is a lethal congenital disorder causing respiratory failure and pulmonary hypertension shortly a

112 with extracorporeal membrane oxygenation for respiratory failure and sepsis between the service being

113 orporeal membrane oxygenation in adults with respiratory failure and sepsis is steadily increasing, b

114 clisib-unrelated TEAEs (respiratory failure; respiratory failure and sepsis).

115 e sleep apnea, 4) patients hospitalized with respiratory failure and suspected of having OHS be disch

116 iated pneumonia presenting with acute severe respiratory failure and systemic inflammation who receiv

117 Respiratory failure and thromboembolism are frequent in

118 She quickly progressed to acute hypoxic respiratory failure and vasoplegic shock.

119 t study of intensive care unit patients with respiratory failure and/or shock, we examined the associ

120 sease/asthma exacerbation, septicemia, acute respiratory failure, and acute renal failure were the mo

121 aking advances in pneumonia, acute hypoxemic respiratory failure, and acute respiratory distress synd

122 attributed to treatment (pneumonitis, acute respiratory failure, and cardiovascular failure).

123 nd were critically ill with acute hypoxaemic respiratory failure, and collected clinical, biomarker,

124 All affected individuals died as a result of respiratory failure, and five of them died within the fi

125 e, dysmorphic facies, cutaneous involvement, respiratory failure, and in the older cases, dilated car

126 Acute kidney injury, acute respiratory failure, and new-onset subclinical atrial fi

127 cted, including data on clinical management, respiratory failure, and patient mortality.

128 mplications such as surgical site infection, respiratory failure, and renal failure contributed the m

129 drome, pneumonia, pneumonitis and hepatitis, respiratory failure, and sudden death [n=1 each]), six (

130 B(+) BALF with overall mortality, death from respiratory failure, and the effect of anti-HHV-6B antiv

131 itis, herpes dermatitis, multiple fractures, respiratory failure, and transient ischaemic attack) and

132 epsis, organ dysfunction (hypotension, acute respiratory failure, and/or acute renal injury), and abs

133 oses of pneumonia, or principal diagnoses of respiratory failure, ARDS, respiratory arrest, or sepsis

134 Of the 747 patients (447 with acute respiratory failure [ARF]), 21.3% had a virus detected (

135 ase were inversely correlated with degree of respiratory failure, as assessed by the ratio of Pao(2)

136 r of 0.7-0.8 mg/dL and increased in-hospital respiratory failure associated with both reduced and ele

137 Respiratory failure associated with COVID-19 has placed

138 cystis jirovecii plays a central role in the respiratory failure associated with Pneumocystis pneumon

139 tive adults with either sepsis or trauma and respiratory failure at 14 university intensive care unit

140 or major antenatal events that cause severe respiratory failure at birth, most extremely preterm inf

141 e proportion of patients with postextubation respiratory failure at day 7 (21% vs 29%; difference, -8

142 ; secondary outcomes included postextubation respiratory failure at day 7, reintubation rates up unti

143 with Covid-19 and severe disease (defined as respiratory failure) at seven hospitals in the Italian a

144 s was used to assess the independent risk of respiratory failure based on various admission SCr, usin

145 Respiratory failure both before and after LVAD implantat

146 COVID-19 pathophysiology includes respiratory failure but involves other organ systems inc

147 vides evidence that coronavirus disease 2019 respiratory failure can be managed similarly to hypoxic

148 Respiratory failure causes death in SMA but the underlyi

149 of patients transferred to a regional severe respiratory failure center that routinely employs admiss

150 e diagnostic approach to patients with acute respiratory failure, circulatory shock, or cardiac arres

151 domized Evaluation of Sedation Titration for Respiratory Failure clinical trial.

152 sed on preliminary clinical reports, hypoxic respiratory failure complicated by acute respiratory dis

153 nakes was likely acute methemoglobinemia and respiratory failure due to severe hypoxia with no observ

154 curve relationship between admission SCr and respiratory failure during hospitalization was observed,

155 Acute kidney injury and acute respiratory failure each occurred in 30% of admissions.

156 ion including etiology and severity of acute respiratory failure enable to identify patients at high

157 of severe forms of COVID-19 and can lead to respiratory failure, especially in older individuals.

158 line impaired function, prematurity, cancer, respiratory failure etiology, ventilation duration, and

159 domized Evaluation of Sedation Titration for Respiratory Failure extubation readiness test) in predic

160 n admission for acute-on-chronic hypercapnic respiratory failure, favoring instead reassessment for N

161 with hemodynamic compromise, with or without respiratory failure, for days or weeks.

162 successful extubation in children with acute respiratory failure from lower respiratory tract disease

163 center cohort of ICU survivors with shock or respiratory failure from surgical and medical ICUs acros

164 nous extracorporeal membrane oxygenation for respiratory failure had neurologic injury.

165 cute kidney injury, cardiac surgery, anemia, respiratory failure, heart failure, cardiac arrest, meta

166 clusions: As compared with HFNC in hypoxemic respiratory failure, helmet NIV improves oxygenation, re

167 lure was categorized as acute kidney injury, respiratory failure, hepatic failure, and hemodynamic fa

168 unocompromised patients with hypoxemic acute respiratory failure, high-flow nasal oxygen when compare

169 The main reason for ICU admission was acute respiratory failure in 111 patients (81.6%), of whom 89

170 als of extracorporeal life support for acute respiratory failure in adults in the 1970s and 1990s fai

171 mic complement activation is associated with respiratory failure in COVID-19 patients and provides a

172 or is therapeutic in acute hyperinflammatory respiratory failure in COVID-19 patients.

173 istress syndrome (ARDS) is a common cause of respiratory failure in critically ill patients and is de

174 ess syndrome (ARDS) remains a major cause of respiratory failure in critically ill patients.

175 za seasons) of cases of influenza-associated respiratory failure in Edmonton, Alberta.

176 irway pressure group, there were no cases of respiratory failure in either of the surfactant-treated

177 Further analysis revealed increased respiratory failure in nonsurvivors.

178 in one patient, and acute renal failure and respiratory failure in one patient) were suspected to be

179 ute respiratory distress syndrome (ARDS) and respiratory failure in patients with coronavirus disease

180 nterest in the role of the nervous system in respiratory failure in people with COVID-19.

181 ved, with the nadir incidence of in-hospital respiratory failure in SCr of 0.7-0.8 mg/dL and increase

182 e safe and effective in reducing the risk of respiratory failure in the 72 hours after treatment.

183 Respiratory failure in the acute respiratory syndrome co

184 n the control group and one episode of acute respiratory failure in the closed-loop group), both of w

185 eatinine as the variables most predictive of respiratory failure in the evaluation cohort.

186 flow nasal oxygen may prevent postextubation respiratory failure in the intensive care unit (ICU).

187 -year-olds mechanically ventilated for acute respiratory failure in the RESTORE (Randomized Evaluatio

188 cter of mobility for ICU patients with acute respiratory failure in U.S.

189 mechanically ventilated patients with acute respiratory failure; in this regard, pulmonary ultrasoun

190 dmission to an intensive care unit involving respiratory failure, intubation, and mechanical ventilat

191 Acute respiratory failure is a common reason for admission to

192 Acute respiratory failure is a frequent complication of Guilla

193 Respiratory failure is a leading cause of SUDEP, and DS

194 ospectively validated biomarker of impending respiratory failure is available.

195 pport in the management of adults with acute respiratory failure is being redefined by advances in te

196 ).Conclusions: Postdischarge morbidity after respiratory failure is common and associated with admiss

197 Progressive respiratory failure is the primary cause of death in the

198 NC) therapy in patients with acute hypoxemic respiratory failure is to not delay intubation.

199 sons for admission to the ICU were hypoxemic respiratory failure leading to mechanical ventilation, h

200 tically ill patients with COVID-19 and acute respiratory failure, low-dose hydrocortisone, compared w

201 Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE).

202 membrane oxygenation (ECMO) in patients with respiratory failure may cause cerebral vasoconstriction

203 breathing, nonintubated patients with acute respiratory failure may have a high respiratory drive an

204 quality of life (HRQL) after pediatric acute respiratory failure.Methods: We assessed functional stat

205 neurological complications in patients with respiratory failure.Methods: We conducted a multicenter,

206 s (surgery, sepsis, pneumonia, pneumothorax, respiratory failure, myocardial infarction, thyrotoxicos

207 momelotinib (acute myeloid leukaemia [n=2], respiratory failure [n=2, with one considered possibly r

208 e [7%] cerebrovascular accident and one [7%] respiratory failure); neither of these deaths were consi

209 on to the intensive care unit for hypoxaemic respiratory failure, no deaths occurred.

210 e used for the management of acute hypoxemic respiratory failure.Objectives: Physiological comparison

211 ation (NIV) failure in acute hypoxic de novo respiratory failure.Objectives: To explore the hypothesi

212 failure can be managed similarly to hypoxic respiratory failure of other etiologies.

213 m pulmonary embolus on day 137, and one from respiratory failure on day 152; one participant in the p

214 e participant in the placebo group died from respiratory failure on day 52.

215 nous extracorporeal membrane oxygenation for respiratory failure on heparin dose, adequacy of anticoa

216 between immediate preimplant and postimplant respiratory failure on outcomes in advanced heart failur

217 The impact of respiratory failure on patients undergoing left ventricu

218 o group), dyspnoea (three [1%] vs two [1%]); respiratory failure (one [<1%] vs three [2%]), myocardia

219 ecause of progressive disease (two [5%]) and respiratory failure (one [2%]).

220 cute kidney failure, one liver toxicity, two respiratory failure, one thromboembolic event, and one s

221 wo decades; in contrast, patients with acute respiratory failure only experienced marked decreases in

222 cantly associated with increased in-hospital respiratory failure (OR 3.11; 95% CI 2.33-4.17), exceedi

223 ependently associated with the risk of acute respiratory failure (OR, 3.54, 95% CI, 1.05-11.96).

224 heart failure (OR, 3.3 [95% CI, 2.8-3.9]) or respiratory failure (OR, 3.7 [95% CI, 3.1-4.4]) and prio

225 se (OR, 1.9; 95% CI, 1.1-3.7; P = 0.04), and respiratory failure (OR, 4.7; 95% CI, 1.1-26.3; P = 0.04

226 za, pneumonia, other respiratory infections, respiratory failure, or airway effects requiring therape

227 /mL and/or C-reactive protein >10 mg/dL) and respiratory failure (oxygen therapy from 0.4 FiO(2) Vent

228 icantly higher in patients with than without respiratory failure (P = 0.008 and P = 0.034).

229 leak (P = 0.427), pneumonia (P = 0.548), and respiratory failure (P = 0.723).

230 We analyzed consecutive patients with severe respiratory failure (PaO2/FIO2 < 85 mm Hg and/or respira

231 piratory infection had more severe hypoxemic respiratory failure (PaO2/FIO2: 106 [66, 160] vs 176 [10

232 domized Evaluation of Sedation Titration for Respiratory Failure patients (5%) with moderate/severe p

233 In a cohort of hospitals caring for acute respiratory failure patients, physical therapy/occupatio

234 chospasm, atelectasis, pulmonary congestion, respiratory failure, pleural effusion, pneumothorax, or

235 n acute respiratory distress syndrome, acute respiratory failure, pneumonia, and sepsis have yielded

236 domized Evaluation of Sedation Titration for Respiratory Failure protocol.

237 Organization Registry, including adults with respiratory failure receiving ECMO via any mode between

238 hock: 12.6% to 6.7%; septic shock with acute respiratory failure receiving invasive mechanical ventil

239 nical ventilation: 20.3% to 11.3%; and acute respiratory failure receiving invasive mechanical ventil

240 ck (22.1% to 15.5%), septic shock with acute respiratory failure receiving invasive mechanical ventil

241 nical ventilation (28.7% to 22.4%) and acute respiratory failure receiving invasive mechanical ventil

242 for septic shock, 0.97 (0.97-0.97) for acute respiratory failure receiving invasive mechanical ventil

243 septic shock, and 0.99 (0.99-0.99) for acute respiratory failure receiving invasive mechanical ventil

244 (21.2% to 10.8%) and septic shock with acute respiratory failure receiving invasive mechanical ventil

245 .4%) but increased among patients with acute respiratory failure receiving invasive mechanical ventil

246 ced therapy in select patients with COVID-19 respiratory failure refractory to traditional critical c

247 0.70; moderate certainty) and postextubation respiratory failure (relative risk, 0.52; 95% CI, 0.30-0

248 1.53; moderate certainty), or postextubation respiratory failure (relative risk, 0.82; 95% CI, 0.48-1

249 extracorporeal membrane oxygenation run for respiratory failure reported to the Extracorporeal Life

250 Severe hypercapnic respiratory failure requiring ICU admission resulted pri

251 te kidney injury occurred in 52% cases, with respiratory failure requiring intubation in 29%, and the

252 h in previously healthy children after acute respiratory failure requiring mechanical ventilation are

253 olites in critically ill children with acute respiratory failure requiring mechanical ventilation due

254 Cr of <=0.4 mg/dL, and 2886 (4.3%) developed respiratory failure requiring mechanical ventilation dur

255 The primary outcome was the occurrence of respiratory failure requiring mechanical ventilation dur

256 predicting septic shock (c-statistic 0.90), respiratory failure requiring mechanical ventilation for

257 dently associated with increased in-hospital respiratory failure requiring mechanical ventilation in

258 ine (SCr) value at admission and the risk of respiratory failure requiring mechanical ventilation in

259 cokinetic in pediatric subjects with primary respiratory failure requiring mechanical ventilation, pr

260 lasmablasts appearing in patients with acute respiratory failure requiring mechanical ventilation.

261 al to 24 months old at follow-up after acute respiratory failure requiring mechanical ventilation.

262 bated inpatients with COVID-19 and hypoxemic respiratory failure requiring oxygen supplementation who

263 had progressive neurologic deterioration and respiratory failure, requiring intensive care unit admis

264 rienced 3 fatal parsaclisib-unrelated TEAEs (respiratory failure; respiratory failure and sepsis).

265 corporeal life support for adults with acute respiratory failure reveals an enthusiasm for the techno

266 understand the risk factors associated with respiratory failure (RF) and fatal lower respiratory tra

267 Risk factors for respiratory failure (RF) and mortality due to RSV were a

268 SUMMARY BACKGROUND DATA: Postoperative respiratory failure (RF), defined as ventilator dependen

269 ients who underwent tracheostomy after acute respiratory failure secondary to COVID-19.

270 Despite this approach, death from respiratory failure secondary to the development and pro

271 sive dyspnoea of insidious onset, hypoxaemic respiratory failure, secondary infections and pulmonary

272 ally ill children with cardiovascular and/or respiratory failure, severe hypoglycemia (blood glucose

273 oped inspiratory stridor and acute hypoxemic respiratory failure shortly after the stent was placed.

274 Understand the Global Impact of Severe Acute Respiratory Failure) study described the management of p

275 ripartum patients with refractory cardiac or respiratory failure supported on extracorporeal membrane

276 rch studies evaluating the outcomes of acute respiratory failure survivors after hospital discharge.

277 2) results from a qualitative study of acute respiratory failure survivors' outcomes after hospital d

278 from surveys of clinical researchers, acute respiratory failure survivors, and caregivers that rated

279 cebo group (16 [11%]), mainly as a result of respiratory failure (ten [7%] vs five [3%]).

280 rophic lateral sclerosis (ALS), end life via respiratory failure, the ability to harness respiratory

281 Covid-19-associated or influenza-associated respiratory failure, the histologic pattern in the perip

282 espectively - that we propose contributes to respiratory failure, the most common cause of death in D

283 sions: In patients with pneumonia with acute respiratory failure treated with HFNC, ROX is an index t

284 unocompromised patients with hypoxemic acute respiratory failure treated with high-flow nasal oxygen.

285 Six (15%) developed acute respiratory failure treated with invasive mechanical ven

286 rials of adult patients with acute hypoxemic respiratory failure, treatment with noninvasive oxygenat

287 domized Evaluation of Sedation Titration for Respiratory Failure) trial.

288 (age 8 weeks to 24 months), which was due to respiratory failure unrelated to malaria.

289 Respiratory failure was defined as PO(2)/FiO(2) ratio of

290 d to be related to everolimus treatment, but respiratory failure was suspected to be related.

291 ts died after a median of 13.5 (10-23) days, respiratory failure was the major cause.

292 d with long-term survival, and an absence of respiratory failure was the strongest predictor of 1-yea

293 Sepsis, acute kidney injury, and acute respiratory failure were associated with mortality.

294 e care unit (ICU) for COVID-19-related acute respiratory failure were enrolled from March 7 to June 1

295 eart dilation, blood vessel irregularity and respiratory failure with concurrently reduced dystrophin

296 rly type 2 myocardial infarction, because of respiratory failure with hypoxia and hemodynamic instabi

297 ogistic regression showed increasing odds of respiratory failure with sC5b-9 (odds ratio 31.9, 95% CI

298 atio, 1.20 [95% CI, 1.03-1.41]; P=0.021) and respiratory failure within 1 week (hazard ratio, 2.54 [9

299 antation, and 1001 (6.1%) patients developed respiratory failure within 1 week after implantation.

300 t becomes generalized, leading to death from respiratory failure within 3-5 years from symptom onset.